Insiders Advisor
  • Stocks
  • World News
  • Business
  • Politics
  • Stocks
  • World News
  • Business
  • Politics

Insiders Advisor

Business

Hims & Hers Health says it will offer compounded GLP-1 injections

by May 22, 2024
May 22, 2024
Hims & Hers Health says it will offer compounded GLP-1 injections

Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday.

Shares of the company surged.

The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December. But GLP-1 medications — such as Ozempic and Wegovy, which have skyrocketed in popularity — were not previously offered as part of that program.

Customers can access the compounded GLP-1 medications via a prescription from a licensed health-care provider on the Hims & Hers platform. Hims & Hers said it plans to make branded GLP-1 medications available to its customers once supply is consistently available.

The company’s oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month.

Even before it added compounded GLP-1s to its portfolio, Hims & Hers said in its fourth-quarter earnings report that it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025. The company plans to offer updated guidance in its next earnings report.

The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage.

GLP-1s mimic a hormone produced in the gut to tamp down a person’s appetite and regulate their blood sugar. When those medications are in shortage, certain manufacturers can prepare a compounded version if they meet U.S. Food and Drug Administration requirements.

The FDA does not review the safety and efficacy of compounded products, which are custom-made alternatives to brand drugs designed to meet a specific patient’s needs.

In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available.

Hims & Hers CEO Andrew Dudum told CNBC that the company is “confident” that customers will be able to access a consistent supply of the compounded medications.

Dudum said Hims & Hers has spent the last year learning about the GLP-1 supply chain and has partnered with one of the largest generic manufacturers in the country that has FDA oversight.

“We have a certain degree of exclusivity with that facility that will guarantee our consumers consistent volume and supply,” he said.

This post appeared first on NBC NEWS
previous post
Thomas Massie, GOP rebel who defied Trump and tried to oust Johnson, survives primary threats
next post
Hims & Hers Health says it will offer compounded GLP-1 injections

Related Posts

UnitedHealth CEO suddenly steps down for ‘personal reasons’

May 13, 2025

JPMorgan begins suing customers who allegedly stole thousands...

October 29, 2024

X sees major outages as Musk claims ‘massive...

March 11, 2025

Temu slashes U.S. ad spending, plummets in App...

April 16, 2025

Some experts have raised the odds of a...

August 15, 2024

Inflation and $2,000 camps are creating a summer...

July 24, 2024

A Silicon Valley exec had $400K stolen by...

July 24, 2024

Peacock raising prices by $2 ahead of the...

April 30, 2024

McDonald’s revenue disappoints as U.S. sales see worst...

February 11, 2025

McDonald’s Snack Wrap is officially returning. Here’s when.

June 3, 2025

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Latest News

    • Time for Israel to take out ‘head of the snake,’ target members of Iranian regime, says former IDF intel chief

      June 14, 2025
    • Israeli official vows ‘We have more surprises coming up’ for Iran following wave of airstrikes

      June 14, 2025
    • ‘All-in’: GOP lawmakers divided on US involvement as Trump pushes Iran for diplomatic end

      June 14, 2025
    • Democratic lawmakers criticize Israel’s defensive strikes against Iran’s nuclear sites

      June 13, 2025
    • Israel’s drone strikes in Iran show why US must halt China’s land grab here: experts

      June 13, 2025
    • Biden-appointed judge thwarts Trump’s attempt to clean house at consumer safety agency

      June 13, 2025

    Categories

    • Business (1,261)
    • Politics (5,976)
    • Stocks (904)
    • World News (457)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: insidersadvisor.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 insidersadvisor.com | All Rights Reserved